Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial
A role of iron as a target to prevent stroke-induced neurodegeneration has been recently revisited due to new evidence showing that ferroptosis inhibitors are protective in experimental ischemic stroke and might be therapeutic in other neurodegenerative brain pathologies. Ferroptosis is a new form o...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Antioxidants |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3921/10/8/1270 |
| _version_ | 1827686065226383360 |
|---|---|
| author | Mònica Millán Núria DeGregorio-Rocasolano Natàlia Pérez de la Ossa Sílvia Reverté Joan Costa Pilar Giner Yolanda Silva Tomás Sobrino Manuel Rodríguez-Yáñez Florentino Nombela Francisco Campos Joaquín Serena José Vivancos Octavi Martí-Sistac Jordi Cortés Antoni Dávalos Teresa Gasull |
| author_facet | Mònica Millán Núria DeGregorio-Rocasolano Natàlia Pérez de la Ossa Sílvia Reverté Joan Costa Pilar Giner Yolanda Silva Tomás Sobrino Manuel Rodríguez-Yáñez Florentino Nombela Francisco Campos Joaquín Serena José Vivancos Octavi Martí-Sistac Jordi Cortés Antoni Dávalos Teresa Gasull |
| author_sort | Mònica Millán |
| collection | DOAJ |
| description | A role of iron as a target to prevent stroke-induced neurodegeneration has been recently revisited due to new evidence showing that ferroptosis inhibitors are protective in experimental ischemic stroke and might be therapeutic in other neurodegenerative brain pathologies. Ferroptosis is a new form of programmed cell death attributed to an overwhelming lipidic peroxidation due to excessive free iron and reactive oxygen species (ROS). This study aims to evaluate the safety and tolerability and to explore the therapeutic efficacy of the iron chelator and antioxidant deferoxamine mesylate (DFO) in ischemic stroke patients. Administration of placebo or a single DFO bolus followed by a 72 h continuous infusion of three escalating doses was initiated during the tPA infusion, and the impact on blood transferrin iron was determined. Primary endpoint was safety and tolerability, and secondary endpoint was good clinical outcome (clinicalTrials.gov NCT00777140). DFO was found safe as adverse effects were not different between placebo and DFO arms. DFO (40–60 mg/Kg/day) reduced the iron saturation of blood transferrin. A trend to efficacy was observed in patients with moderate-severe ischemic stroke (NIHSS > 7) treated with DFO 40–60 mg/Kg/day. A good outcome was observed at day 90 in 31% of placebo vs. 50–58% of the 40–60 mg/Kg/day DFO-treated patients. |
| first_indexed | 2024-03-10T09:03:11Z |
| format | Article |
| id | doaj.art-4d8db7d59d7d4d119ea5ec8697cadfdb |
| institution | Directory Open Access Journal |
| issn | 2076-3921 |
| language | English |
| last_indexed | 2024-03-10T09:03:11Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antioxidants |
| spelling | doaj.art-4d8db7d59d7d4d119ea5ec8697cadfdb2023-11-22T06:36:40ZengMDPI AGAntioxidants2076-39212021-08-01108127010.3390/antiox10081270Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical TrialMònica Millán0Núria DeGregorio-Rocasolano1Natàlia Pérez de la Ossa2Sílvia Reverté3Joan Costa4Pilar Giner5Yolanda Silva6Tomás Sobrino7Manuel Rodríguez-Yáñez8Florentino Nombela9Francisco Campos10Joaquín Serena11José Vivancos12Octavi Martí-Sistac13Jordi Cortés14Antoni Dávalos15Teresa Gasull16Department of Neurosciences, Hospital Germans Trias i Pujol, 08916 Badalona, Barcelona, SpainDepartment of Neurosciences, Hospital Germans Trias i Pujol, 08916 Badalona, Barcelona, SpainDepartment of Neurosciences, Hospital Germans Trias i Pujol, 08916 Badalona, Barcelona, SpainDepartment of Neurosciences, Hospital Germans Trias i Pujol, 08916 Badalona, Barcelona, SpainDepartment of Clinical Pharmacology, Hospital Germans Trias i Pujol, 08916 Badalona, Barcelona, SpainDepartment of Pharmacy, Hospital Germans Trias i Pujol, 08916 Badalona, Barcelona, SpainDepartment of Neurology, Hospital Dr. Josep Trueta, 17007 Girona, SpainClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela, Hospital Clínico Universitario, Universidade de Santiago de Compostela, 15706 Santiago de Compostela, SpainDepartment of Neurology, Hospital Clínico Universitario, 15706 Santiago de Compostela, SpainDepartment of Neurology, Hospital La Princesa, 28006 Madrid, SpainClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela, Hospital Clínico Universitario, Universidade de Santiago de Compostela, 15706 Santiago de Compostela, SpainDepartment of Neurology, Hospital Dr. Josep Trueta, 17007 Girona, SpainDepartment of Neurology, Hospital La Princesa, 28006 Madrid, SpainCellular and Molecular Neurobiology Research Group, Department of Neurosciences, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Barcelona, SpainDepartment of Statistics and Operations Research, Universitat Politècnica de Catalunya (UPC), 08028 Barcelona, SpainDepartment of Neurosciences, Hospital Germans Trias i Pujol, 08916 Badalona, Barcelona, SpainDepartment of Neurosciences, Hospital Germans Trias i Pujol, 08916 Badalona, Barcelona, SpainA role of iron as a target to prevent stroke-induced neurodegeneration has been recently revisited due to new evidence showing that ferroptosis inhibitors are protective in experimental ischemic stroke and might be therapeutic in other neurodegenerative brain pathologies. Ferroptosis is a new form of programmed cell death attributed to an overwhelming lipidic peroxidation due to excessive free iron and reactive oxygen species (ROS). This study aims to evaluate the safety and tolerability and to explore the therapeutic efficacy of the iron chelator and antioxidant deferoxamine mesylate (DFO) in ischemic stroke patients. Administration of placebo or a single DFO bolus followed by a 72 h continuous infusion of three escalating doses was initiated during the tPA infusion, and the impact on blood transferrin iron was determined. Primary endpoint was safety and tolerability, and secondary endpoint was good clinical outcome (clinicalTrials.gov NCT00777140). DFO was found safe as adverse effects were not different between placebo and DFO arms. DFO (40–60 mg/Kg/day) reduced the iron saturation of blood transferrin. A trend to efficacy was observed in patients with moderate-severe ischemic stroke (NIHSS > 7) treated with DFO 40–60 mg/Kg/day. A good outcome was observed at day 90 in 31% of placebo vs. 50–58% of the 40–60 mg/Kg/day DFO-treated patients.https://www.mdpi.com/2076-3921/10/8/1270irondeferoxamineantioxidantferroptosisneuroprotectionoutcome |
| spellingShingle | Mònica Millán Núria DeGregorio-Rocasolano Natàlia Pérez de la Ossa Sílvia Reverté Joan Costa Pilar Giner Yolanda Silva Tomás Sobrino Manuel Rodríguez-Yáñez Florentino Nombela Francisco Campos Joaquín Serena José Vivancos Octavi Martí-Sistac Jordi Cortés Antoni Dávalos Teresa Gasull Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial Antioxidants iron deferoxamine antioxidant ferroptosis neuroprotection outcome |
| title | Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial |
| title_full | Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial |
| title_fullStr | Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial |
| title_full_unstemmed | Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial |
| title_short | Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial |
| title_sort | targeting pro oxidant iron with deferoxamine as a treatment for ischemic stroke safety and optimal dose selection in a randomized clinical trial |
| topic | iron deferoxamine antioxidant ferroptosis neuroprotection outcome |
| url | https://www.mdpi.com/2076-3921/10/8/1270 |
| work_keys_str_mv | AT monicamillan targetingprooxidantironwithdeferoxamineasatreatmentforischemicstrokesafetyandoptimaldoseselectioninarandomizedclinicaltrial AT nuriadegregoriorocasolano targetingprooxidantironwithdeferoxamineasatreatmentforischemicstrokesafetyandoptimaldoseselectioninarandomizedclinicaltrial AT nataliaperezdelaossa targetingprooxidantironwithdeferoxamineasatreatmentforischemicstrokesafetyandoptimaldoseselectioninarandomizedclinicaltrial AT silviareverte targetingprooxidantironwithdeferoxamineasatreatmentforischemicstrokesafetyandoptimaldoseselectioninarandomizedclinicaltrial AT joancosta targetingprooxidantironwithdeferoxamineasatreatmentforischemicstrokesafetyandoptimaldoseselectioninarandomizedclinicaltrial AT pilarginer targetingprooxidantironwithdeferoxamineasatreatmentforischemicstrokesafetyandoptimaldoseselectioninarandomizedclinicaltrial AT yolandasilva targetingprooxidantironwithdeferoxamineasatreatmentforischemicstrokesafetyandoptimaldoseselectioninarandomizedclinicaltrial AT tomassobrino targetingprooxidantironwithdeferoxamineasatreatmentforischemicstrokesafetyandoptimaldoseselectioninarandomizedclinicaltrial AT manuelrodriguezyanez targetingprooxidantironwithdeferoxamineasatreatmentforischemicstrokesafetyandoptimaldoseselectioninarandomizedclinicaltrial AT florentinonombela targetingprooxidantironwithdeferoxamineasatreatmentforischemicstrokesafetyandoptimaldoseselectioninarandomizedclinicaltrial AT franciscocampos targetingprooxidantironwithdeferoxamineasatreatmentforischemicstrokesafetyandoptimaldoseselectioninarandomizedclinicaltrial AT joaquinserena targetingprooxidantironwithdeferoxamineasatreatmentforischemicstrokesafetyandoptimaldoseselectioninarandomizedclinicaltrial AT josevivancos targetingprooxidantironwithdeferoxamineasatreatmentforischemicstrokesafetyandoptimaldoseselectioninarandomizedclinicaltrial AT octavimartisistac targetingprooxidantironwithdeferoxamineasatreatmentforischemicstrokesafetyandoptimaldoseselectioninarandomizedclinicaltrial AT jordicortes targetingprooxidantironwithdeferoxamineasatreatmentforischemicstrokesafetyandoptimaldoseselectioninarandomizedclinicaltrial AT antonidavalos targetingprooxidantironwithdeferoxamineasatreatmentforischemicstrokesafetyandoptimaldoseselectioninarandomizedclinicaltrial AT teresagasull targetingprooxidantironwithdeferoxamineasatreatmentforischemicstrokesafetyandoptimaldoseselectioninarandomizedclinicaltrial |